Screener
CURE vs LABD
Direxion Daily Healthcare Bull 3X Shares vs Direxion Daily S&P Biotech Bear 3X Shares
Key differences
- CURE costs 0.13% less per year.
- CURE follows a leveraged strategy; LABD uses inverse.
- Over the last 3 years, CURE has delivered higher annualized returns.
Side-by-side comparison
| CURE | LABD | |
|---|---|---|
| Annual cost (TER) | 0.94% | 1.07% |
| Fund size (AUM) | $138M | $69M |
| Since | 2011 | 2015 |
| Dividend yield | 1.33% | 6.38% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | leveraged | inverse |
| CAGR 1Y | +31.7% | -82.9% |
| CAGR 3Y | +0.8% | -50.8% |
| CAGR 5Y | +0.7% | -42.0% |
| Sharpe 3Y | 0.14 | -0.52 |
| Volatility 1Y | 42.92% | 74.72% |
| Max drawdown | -69.19% | -99.98% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to CURE and LABD
Explore further